Subject
Obstetrics and Gynecology,Oncology
Reference12 articles.
1. Center for Drug Evaluation and Research, 2022. FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma [WWW Document]. FDA. URL https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-and-lenvatinib-advanced-endometrial-carcinoma (accessed 9.26.23).
2. Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer;Di Legge;Int J Gynecol Cancer.,2011
3. Pembrolizumab plus chemotherapy in advanced endometrial cancer;Eskander;N. Engl. J. Med.,2023
4. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model;Kimura;Cancer Sci.,2018
5. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial;Makker;Lancet Oncol,2019
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献